FRMD4A-cytohesin signaling modulates the cellular release of tau.
Xu YanNiko-Petteri NykänenCecilia A BrunelloAnnakaisa HaapasaloMikko HiltunenRiikka-Liisa UronenHenri J HuttunenPublished in: Journal of cell science (2016)
One of the defining pathological features of Alzheimer's disease is the intraneuronal accumulation of tau (also known as MAPT) protein. Tau is also secreted from neurons in response to various stimuli and accumulates in the cerebrospinal fluid of Alzheimer's disease patients. Tau pathology might spread from cell to cell through a mechanism involving secretion and uptake. Here, we developed an assay to follow cellular release and uptake of tau dimers. Individual silencing of ten common late-onset Alzheimer's disease risk genes in HEK293T cells expressing the tau reporters suggested that FRMD4A is functionally linked to tau secretion. FRMD4A depletion by using RNA interference (RNAi) reduced and overexpression increased tau secretion. The activity of cytohesins, interactors of FRMD4A and guanine-nucleotide-exchange factors of Arf6, was necessary for FRMD4A-induced tau secretion. Increased Arf6 and cell polarity signaling through Par6 and atypical protein kinase Cζ (aPKCζ) stimulated tau secretion. In mature cortical neurons, FRMD4A RNAi or inhibition of cytohesins strongly upregulated secretion of endogenous tau. These results suggest that FRMD4A, a genetic risk factor for late-onset Alzheimer's disease, regulates tau secretion by activating cytohesin-Arf6 signaling. We conclude that genetic risk factors of Alzheimer's disease might modulate disease progression by altering tau secretion.
Keyphrases
- binding protein
- cerebrospinal fluid
- late onset
- risk factors
- end stage renal disease
- single cell
- early onset
- chronic kidney disease
- cell proliferation
- signaling pathway
- genome wide
- oxidative stress
- protein kinase
- spinal cord injury
- ejection fraction
- high throughput
- dna methylation
- peritoneal dialysis
- prognostic factors
- diabetic rats
- mild cognitive impairment